BIYKEM BOZKURT to Double-Blind Method
This is a "connection" page, showing publications BIYKEM BOZKURT has written about Double-Blind Method.
Connection Strength
0.153
-
Baseline characteristics in the SYNCHRONIZE?-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes. Diabetes Obes Metab. 2026 Feb; 28(2):1490-1498.
Score: 0.045
-
Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE?-1). Diabetes Obes Metab. 2026 Jan; 28(1):337-346.
Score: 0.044
-
Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation. 2001 Feb 27; 103(8):1044-7.
Score: 0.032
-
Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF). J Card Fail. 2011 Aug; 17(8):634-42.
Score: 0.016
-
Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure. Circulation. 2001 Feb 20; 103(7):973-80.
Score: 0.008
-
Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation. 1999 Jun 29; 99(25):3224-6.
Score: 0.007